Gilead Reports the EMA’s MAA and EU-M4all Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk
Shots:
- The EMA has accepted MAA & EU-M4all as well as granted priority review to lenacapavir (HIV-1 capsid inhibitor) for PrEP in humans at risk of HIV; MAA will be applicable in 30 EEA states (incl. Norway, Iceland & Liechtenstein)
- MAA was based on P-III (PURPOSE 1 & PURPOSE 2) trials assessing lenacapavir (SC; twice yearly) vs Truvada (F/TDF; PO, QD), where PURPOSE 1 focussed on cisgender women, while PURPOSE 2 assessed gender-diverse individuals incl. geographically diverse range of cisgender men
- PURPOSE 1 showed 0 infections & 100% risk reduction & superiority in women while PURPOSE 2 showed 99.9% non-infection rate (2 pts acquired HIV) & 96% risk reduction & superiority in contrast to bHIV
Ref: Businesswire | Image: Gilead
Related News:- Gilead Reports US FDA’s NDA Acceptance of Lenacapavir for Pre-Exposure Prophylaxis (PreP) to Prevent HIV in Individuals at Risk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
